PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 12, 2025

Chemoimmunotherapy for Patients with Resectable Non-Small Cell Lung Carcinoma: Real-World Data Analysis from a Surgical Point of View

View Full Paper
Ask AI
Bookmark
Share

Authors

NDNiels Michael Dörr-Jerat

Discussion

Loading...

Member takes

Overview

Retrospective analysis of neoadjuvant chemoimmunotherapy effects on surgical outcomes in NSCLC patients, indicating clinical feasibility.

Key Points

  • Neoadjuvant chemoimmunotherapy before lung resection showed a 33% complete pathological response rate.
  • Among patients, 89% achieved tumor-free margins after surgical intervention per final pathology.
  • Analysis included 18 patients, with stable disease in 56% and a mean surgical delay of 117 days.
  • The study highlights challenges and successes of surgical methods post-neoadjuvant treatment for NSCLC.

Cite This Study

Niels Michael Dörr-Jerat (2025) studied this question.

synapsesocial.com/papers/68d44f6931b076d99fa564ffhttps://doi.org/10.46889/jsrp.2025.6302
View Full Paper
Ask AI
Bookmark
Share